DGAP-News: CureVac / Key word: Financing/Corporate Action CureVac Announces Pricing of USD450 million Follow-on Public Offering of Common Shares 2021-01-28 / 07:00 The issuer is solely responsible.
Press release content from Accesswire. The AP news staff was not involved in its creation.
CureVac Announces Proposed Public Offering of Common Shares
January 26, 2021 GMT
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 25, 2021 / CureVac N.V. (NASDAQ:CVAC) (“CureVac” or the “Company”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer and sell in an underwritten public offering 5,000,000 common shares. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions. All the shares will be offered by CureVac.